论文部分内容阅读
目的:研究阿托伐他汀联合缬沙坦对永久性房颤患者心脏重构及炎症因子水平的影响。方法:选取2015年1月至2016年1月收入我院的永久性房颤患者90例为研究对象。随机数字表法将患者分为治疗组和对照组(每组各45例),对照组使用胺碘酮治疗,治疗组使用阿托伐他汀联合缬沙坦治疗,比较两组患者的心脏重构指标及炎症因子水平。结果:治疗组总有效率为87.9%,显著高于对照组的70.2%(χ2=6.498,P<0.05)。治疗后两组心脏重构指标均显著降低(P<0.05),且与对照组相比,治疗组左房内径水平降低显著(P<0.05)。两组hs-CRP、NT-proBNP水平治疗后均显著降低(P<0.05),且与对照组相比,治疗组hs-CRP、NT-proBNP水平降低显著(P<0.05)。治疗后两组均无不良反应发生,且两组肝功能、肾功能及电解质等常规未见异常。结论:阿托伐他汀联合缬沙坦治疗永久性房颤疗效好,减少了心脏重构,降低了炎症反应,值得临床推广应用。
Objective: To investigate the effects of atorvastatin combined with valsartan on cardiac remodeling and inflammatory cytokines in patients with permanent atrial fibrillation. Methods: From January 2015 to January 2016, 90 patients with permanent AF who were admitted to our hospital were enrolled in this study. Patients were divided into treatment group (n = 45) and control group (n = 45) by random number table. Amiodarone group was used as the control group. Atorvastatin combined with valsartan was used as the treatment group. Heart reconstruction Indicators and levels of inflammatory cytokines. Results: The total effective rate was 87.9% in the treatment group, which was significantly higher than 70.2% in the control group (χ2 = 6.498, P <0.05). The indexes of cardiac remodeling in both groups were significantly decreased after treatment (P <0.05). Compared with the control group, the left atrial diameter decreased significantly (P <0.05). The levels of hs-CRP and NT-proBNP in both groups were significantly decreased after treatment (P <0.05). Compared with the control group, the levels of hs-CRP and NT-proBNP in the two groups decreased significantly (P <0.05). No adverse reactions occurred in both groups after treatment, and no abnormalities such as liver function, renal function and electrolytes were observed in both groups. Conclusion: Atorvastatin combined with valsartan in the treatment of permanent atrial fibrillation has a good curative effect, reduces cardiac remodeling, reduces the inflammatory reaction and deserves clinical application.